
Group sequential designs zzso which provide for interim monitoring of efficacy data and allow potential early trial termination while preserving the type I error rate, have become commonplace in zzso clinical zzso Although ethically appealing, zzso tend to overestimate the true treatment effect size at early interim zzso zzso of the treatment effect may zzso the benefit of a drug and provide imprecise information for physicians and their patients about a drug's true zzso The cause and effect of such a phenomenon are generally not well understood by many in clinical trial zzso In this article, we provide a zzso explanation for why the phenomenon of zzso in zzso zzso The potential zzso of the magnitude of the treatment effect is of particular concern in zzso in which the more zzso zzso of zzso survival has increasingly been adopted as the primary zzso in pivotal phase III zzso 

